Download ChanTest: Ion Channel Cell lines validated on

Human Cardiomyocyte Assay
ChanTest Pre-clinical Safety Toxicology:
Human stem cell-derived cardiomyocytes now available for
assessing cardiac liability
Traditional in vitro cardiac safety assays evaluate risk by measuring action potential
parameters in whole-heart (Langendorff), dissected heart (Purkinje fiber), or isolated
single cells (native cardiomyocytes). While each of these assays provides important
information, all are conducted on non-human mammalian preparations (e.g. rabbit, dog,
or guinea pig). ChanTest now offers a human cardiomyocyte assay that detects drug
effects on cardiac action potential parameters.
Drug effects are assessed in ventricular-type cardiomyocytes derived from human
embryonic stem cells. Action potential parameters are measured from cardiomyocytes
using perforated patch current-clamp technology. In addition to detecting action
potential prolongation (i.e. QT risk) and early afterdepolarizations (EADs) due to hERG
channel inhibition, this assay also detects effects on phase 2 depolarization (calcium
channel effects), and multiple ion channel effects.
Benefits:
• Human complement of ion channels
• Rapid turnaround
• Cost-effective
• Robust pharmacological responses
• Stable platform validated with most common compounds
• Ideal for screening multiple ion channels in a single test system
The leading expert in ion channels and GPCR (G-protein coupled receptors),
ChanTest’s mission is to help global pharmaceutical and biotech customers speed the
drug-discovery and development process, save time and money, and ultimately – to help
make better, safer drugs. ChanTest offers integrated ion channel and GPCR services
(both automated high-throughput and GLP), cell lines, membranes, and reagents that
cover nearly half of the known drugable genome. Since its inception in 1998, ChanTest
has tested more than 20,000 compounds for more than 500 pharmaceutical and biotech
companies worldwide. ChanTest continues to expand its library of ion channel and ion
channel/GPCR-expressing cell lines, making it the most comprehensive catalog in the
industry. Now, for the first time, customers can profile the efficacy and selectivity of drug
leads against an extensive set of ion channels and GPCRs in functional, cell-based
assays. Because of ChanTest’s seminal role in this field, along with the company’s
uncompromising commitment to quality, ChanTest was named “most trusted fee-forservice provider” for ion channel screening in the HTStec Ion Channel Trends Survey for
two years in a row. ChanTest is based in Cleveland, Ohio, U.S.A. For more information,
contact Bob Schultek at [email protected].